Business Wire

Murata Manufacturing: 3-in-1 Soil Sensors Help Maximize Crop Yield and Quality in Smart Agriculture

9.5.2022 06:00:00 EEST | Business Wire | Press release

Share

Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) has introduced a highly accurate three-in-one soil sensor for data-driven sustainable agriculture. By simultaneously monitoring the electrical conductivity (EC), water content and temperature of the soil, the sensor enables farmers to maximize the yield and quality of crops while minimizing resources such as water and fertilizers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220508005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

[Murata Manufacturing Co., Ltd.] soil sensor (Photo: Business Wire)

The tip of the soil sensor contains a grid of 9 extra-sensitive electrodes that provide consistent measurements of the soil’s EC. Using unique algorithms, these electrodes help measure and compare the EC of pore water, which is the water in between the soil particles, to the volume of the soil’s natural nutrients and added fertilizers. These EC measurements are not affected by soil moisture content, thereby eliminating uncertainty in the soil and contributing to improving crop quality and yield by optimizing fertilizers.

Knowing the water content of the soil also enables the grower to irrigate the soil in an accurate and timely manner, saving water. As well as monitoring soil conditions, the robust and reliable sensor can monitor the water quality of rivers and lakes.
“We have conducted demonstration tests using our soil sensors on a variety of fields and crops to verify their effectiveness,” says Yoshiyuki Oba, developer, Murata. “By using data for management and control, the soil sensors contribute to labor-saving in agricultural work and reduce waste of valuable resources such as water and fertilizer. They also contribute to achieving Sustainable Development Goals (SDGs), such as environmental problems like salt damage and the accompanying food problems caused by global climate change.”

Protected to IP68 equivalent for dust and water, including rust proofing for use in harsh environments, these high-performing and energy-efficient soil sensors can run on three AA batteries for over half a year if the measurement interval is once every 30 minutes. The multi-interface sensors also support UART, RS232E, RS485, SDI-12, and RS485 MODBUS, making them compatible with existing crop management systems.

For more information, please visit: https://www.murata.com/en-global/products/sensor/soil

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact:
Murata Manufacturing Co., Ltd.
Wakana Nakamura, prsec_mmc@murata.com
Corporate Communications Department

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release

Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye